Jared Ryan Kelly Purchases 29,500 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Jared Ryan Kelly acquired 29,500 shares of the stock in a transaction dated Thursday, February 12th. The shares were bought at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the completion of the transaction, the insider owned 109,000 shares of the company’s stock, valued at approximately C$126,440. This represents a 37.11% increase in their position.

Jared Ryan Kelly also recently made the following trade(s):

• On Wednesday, February 11th, Jared Ryan Kelly acquired 5,600 shares of Oncolytics Biotech stock. The stock was purchased at an average price of C$1.15 per share, for a total transaction of C$6,440.00.

Oncolytics Biotech Price Performance

Oncolytics Biotech Inc. has a 52 week low of C$0.44 and a 52 week high of C$2.08. The company has a fifty day simple moving average of C$14.90 and a two-hundred day simple moving average of C$13.11. The firm has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99.

Oncolytics Biotech (TSE:ONC) last issued its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, research analysts expect that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.